354 results on '"Gainor, J."'
Search Results
52. 65O Phase III LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy
53. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
54. 1O Safety, pharmacokinetics, efficacy, and biomarker results of SRK-181 (a latent TGFβ1 inhibitor) from a phase I trial (DRAGON trial)
55. Monstrous Regiment (1975-1993)
56. LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722
57. P1.12B.02 Mechanisms of Resistance to First-Line vs Later-Line Alectinib in ALK Fusion-Positive Non-Small Cell Lung Cancer.
58. 1170P Updated efficacy and safety data from the phase I/II ARROW study of pralsetinib in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC)
59. 984P Relationship between RET fusion partner and treatment outcomes in patients (pts) with non-small cell lung cancer (NSCLC) from the phase I/II ARROW study and real-world data (RWD)
60. MA15.09 LCMC3: Long-Term Disease-Free and Overall Survival and their Association with ctDNA after Neoadjuvant Atezolizumab for NSCLC
61. Real-World Patterns of Cranial Radiation Therapy Among Patients with Brain Metastases from Non-Small Cell Lung Cancer in the Era of CNS-Penetrant Tyrosine Kinase Inhibitors
62. Impact of Radiation Therapy on Long-Term Survival in Patients with KRAS-Mutant Stage IV NSCLC Treated with Immune Checkpoint Inhibitors
63. 68O Frequency of clinical acquired RAS-MAPK pathway resistance alterations in patients treated with KRASG12C inhibitors: An individual patient meta-analysis
64. 130P COM701 ± nivolumab: Preliminary results of antitumor activity from a phase I study in patients with metastatic NSCLC who have received prior PD-1/PD-L1 inhibitor
65. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
66. Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer
67. Quantitative Evaluation of Normal Lung Density Changes in Non-Small Cell Lung Cancer Patients Treated With Radiotherapy and PD-1 Immune Checkpoint Inhibitors
68. Fabian drama
69. SO-31 ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer
70. Selpercatinib (LOXO-292) in patients with RET-Fusion+ non small-cell lung cancer (NSCLC)
71. Selpercatinib (LOXO-292) in patients with RET-Fusion+ non small-cell lung cancer (NSCLC)
72. OA06.06 Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study
73. P75.03 KEYNOTE-U01: A Phase 2 Umbrella Study of Investigational Agents Plus Pembrolizumab-Based Therapy for Advanced NSCLC
74. P14.26 Diminished Efficacy of PD-(L)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma is Impacted by KRAS Mutation Status
75. Registrational dataset from the phase 1/2 ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion plus non-small-cell lung cancer (NSCLC)
76. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer
77. OA05.02 Analysis of Resistance Mmechanisms to Pralsetinib in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) from the ARROW Study
78. Activité intracrânienne du selpercatinib (LOXO-292) chez les patients atteints d’un cancer bronchique non à petites cellules (CBNPC) exprimant le gène de fusion RET dans le cadre de l’essai LIBRETTO-001
79. 41P Efficacy of first-line (1L) nivolumab (N) + ipilimumab (I) by tumor histologic subtype in patients (pts) with metastatic nonsquamous NSCLC (mNSQ-NSCLC)
80. GRANVILLE BARKER ON THEATRE: SELECTED ESSAYS. Theatre Makers series Barker Harley Granville Chambers Colin Nelson Richard
81. Dance Nationand Its Representational Challenges
82. Susan Glaspell and Sophie Treadwell: Staging Feminism and Modernism, 1915-1941
83. Albee’s The Goat
84. Screening of ‘unbiased’ immobilized peptide library vs. proteases: An approach for rapid determination of substrate specificity and selectivity
85. Immobilized peptide arrays: A new technology for the characterization of protease function
86. Relationship between structure and bio-availability in a series of hydroxamate based metalloprotease inhibitors
87. The synthesis and coupling efficiency of 7-hydroxycoumarin-4-propionic acid, a fluorescent marker useful in immobilized substrate libraries
88. MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC
89. MS01.01 Biological Mechanisms of Resistance
90. Susan Glaspell in Context : American Theater, Culture, and Politics, 1915-48
91. Performing America : Cultural Nationalism in American Theater
92. The Feminist Possibilities of Dramatic Realism
93. MA04.05 Outcomes in NSCLC Patients Treated with First-Line Pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100%
94. MA26.03 Activity of Osimertinib and the Selective RET Inhibitor BLU-667 in an EGFR-Mutant Patient with Acquired RET Rearrangement
95. MA16.08 Clinical Utility of Detecting ROS1 Genetic Alterations in Plasma
96. P1.04-21 The Utility of PD-L1/CD8 Dual Immunohistochemistry for Prediction of Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)
97. P2.04-23 Immune-Related Adverse Events: The Growing Pains of Immunooncology
98. MA08.05 Brain Penetration of Lorlatinib and Cumulative Incidence Rates for CNS and Non CNS Progression from a Phase 1/2 Study
99. Competitive ballroom dancing is back!
100. P3.07-012 Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer and Liver Metastases
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.